CME Group Files 8-K Report

Ticker: CME · Form: 8-K · Filed: 2024-12-11T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-k, compliance

TL;DR

CME Group filed an 8-K, standard regulatory update.

AI Summary

On December 11, 2024, CME Group Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial transactions or material events are detailed in the provided excerpt, suggesting it may be a routine filing or related to exhibit submissions.

Why It Matters

This filing indicates CME Group is adhering to regulatory reporting requirements, which is standard practice for publicly traded companies and provides transparency to investors.

Risk Assessment

Risk Level: low — The filing appears to be a routine regulatory disclosure without any immediately apparent negative or positive material events.

Key Numbers

Key Players & Entities

FAQ

What specific event triggered this 8-K filing?

The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', suggesting it's related to regulatory compliance or the submission of financial documents, rather than a single discrete event.

What is the significance of the 'Former Company' information?

The filing notes that CME Group Inc. was formerly known as CHICAGO MERCANTILE EXCHANGE HOLDINGS INC, with a name change date of August 2, 2001.

What is the primary business of CME Group Inc. according to the filing?

The Standard Industrial Classification code indicates CME Group Inc. operates in 'SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES'.

Where are CME Group Inc.'s principal executive offices located?

The principal executive offices are located at 20 South Wacker Drive, Chicago, Illinois, 60606.

What is the fiscal year end for CME Group Inc.?

The fiscal year end for CME Group Inc. is December 31.

From the Filing

0001193125-24-274928.txt : 20241211 0001193125-24-274928.hdr.sgml : 20241211 20241211091601 ACCESSION NUMBER: 0001193125-24-274928 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241211 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241211 DATE AS OF CHANGE: 20241211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CME GROUP INC. CENTRAL INDEX KEY: 0001156375 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES [6200] ORGANIZATION NAME: 09 Crypto Assets IRS NUMBER: 364459170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31553 FILM NUMBER: 241540362 BUSINESS ADDRESS: STREET 1: 20 S. WACKER DR. CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 3129301000 MAIL ADDRESS: STREET 1: 20 S. WACKER DR. CITY: CHICAGO STATE: IL ZIP: 60606 FORMER COMPANY: FORMER CONFORMED NAME: CHICAGO MERCANTILE EXCHANGE HOLDINGS INC DATE OF NAME CHANGE: 20010802 8-K 1 d777185d8k.htm 8-K 8-K false 0001156375 0001156375 2024-12-11 2024-12-11     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 11, 2024     CME GROUP INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-31553   36-4459170 (State or Other Jurisdiction of Incorporation)   (Commission File No.)   (IRS Employer Identification No.)   20 South Wacker Drive   Chicago   Illinois    60606 (Address of Principal Executive Offices)        (Zip Code) Registrant’s telephone number, including area code: (312) 930-1000 N/A (Former Name or Former Address, if Changed Since Last Report)     Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol   Name of each exchange on which registered Class A Common Stock   CME   Nasdaq Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       Item 7.01 Regulation FD Disclosure. On December 11, 2024, CME Group Inc. communicated changes to its Clearing House collateral fee schedule to its Clearing Members via Advisory Notice 24-383 and communicated pricing changes to its clients via Special Executive Report 9482. Copies of these notices have been posted to the Company’s website. The information furnished under Item 7.01 of this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwi

View on Read The Filing